Taking this into account, the use of new neurocognitive endophenotypes would have clinical utility, especially in less-studied cognitive impairments such as social cognition/theory of mind and executive function in AD, along with new biomarkers like IGF-I, stress, and neuroinflammation, analyzed together. This evidence concerns the gene IGF1 and Alzheimer disease.